of rheumatoid nodules in four patients with RA in eight to 12 weeks after the start of treatment, parallel with a decrease in disease activity.
We also have used sulphasalazine regularly for the treatment of RA since 1983,2 but we have not found any favourable effect on the extra-articular manifestations of the disease. After reading Englert's article, therefore, we decided to carry out a trial of sulphasalazine treatment in RA.
During a 24 week prospective trial we followed up seven patients with RA, who had subcutaneous rheumatoid nodules. They received 2 g/day sulphasalazine. Nine patients with RA and rheumatoid nodules treated with gold (sodium aurothiomalate) and six receiving various types of non-steroidal anti-inflammatory drugs (NSAIDs) alone served as controls.
Patients were randomly allocated to receive sulphasalazine, gold, or only NSAID. Intraarticular corticosteroids were not allowed during the course of the study, but some patients continued to receive oral prednisolone 7 5 mg daily or less, which had been started previously. All doses remained constant throughout the trial. There was no statistically significant difference in the characteristics of the patients at the start of the study among the three groups (p>0 05, Mann-Whitney U test).
All patients had active classical or definite RA according to American Rheumatism Association criteria and all were seropositive for rheumatoid factor. The size of the rheumatoid nodules varied between 7 and 28 mm, their localisation was typical (over olecranon, extensor surface of the forearm, proximal interphalangeal joints, patella, Achilles tendon). To assess the disease activity we used the following indices: Ritchie articular index, visual analogue pain scale, duration of early morning stiffness, hand grip strength, and erythrocyte sedimentation rate. Disease activity was considered to be decreased when at least four of the five variables improved by 500/o or more.
At the end of the 24 week observation period no difference in the rate of regression of rheumatoid nodules could be detected between the patients taking sulphasalazine and those in the other two groups.
In the group taking sulphasalazine the size of the subcutaneous nodules had decreased in one patient only, but at the same time improvement in disease activity was seen in five patients. In the control group treated with gold we noticed a diminution of nodules in two patients and a decrease of inflammatory activity in six. In the group taking an NSAID alone the nodule size had decreased in three patients and the disease activity had diminished in four. The use of oral corticosteroids had no influence on the regression of the rheumatoid nodules. The table shows the results of our study.
Complete disappearance of nodules could not be found in any of the 22 patients. It is noteworthy that, like other investigators, 3 4 we found no relation between the regression of nodules and the reduction of disease activity.
Thus 
